HOME
Latest news:

- VCN Biosciences to present data with VCN-01 in patients with pancreatic cancer at ESMO 2019.
> Read more
...........................................

- VCN Biosciences to present Two Investor Conferences in May 2019.
> Read more
...........................................

- VCN Biosciences announces the initiation of a Clinical Trial combining VCN-01 with Durvalumab.
> Read more

 

Vcn Biosciences

VCN Biosciences SL is a privately-owned company focused in the development of new therapeutic approaches for tumors that lack effective treatment. The company uses an oncolytic adenovirus technology platform to design highly selective and efficient agents that replicate and self-amplify exclusively in tumor cells. The selectivity of VCN oncolytic adenoviruses allows their systemic administration, which is especially relevant for the treatment of disseminated cancer. Contrary to chemotherapy, the ability of oncolytic virus to self-amplify in tumor cells results in an effective dose increase with time. These properties highlight VCN candidates as promising alternatives for the treatment of refractory tumors such as pancreatic adenocarcinomas, which is the current tumor target for VCN-01.